A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).
This study investigates treatment of durvalumab or placebo therapy combined with FLOT chemotherapy (flurouroacil + leucovorin + oxaliplatin + docetaxel) given before surgery (neoadjuvant) and durvalumab or placebo therapy combined with FLOT chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer, and also to better understand the studied disease and associated health problems.
Key Inclusion Criteria:
Key Exclusion Criteria:
Ciudad Autonoma Buenos Aires, 1093, Argentina
Ciudad de Buenos Aires, 1280, Argentina
Ciudad de Buenos Aires, C1426ANZ, Argentina
North York, Ontario M2K 1E1, Canada
Mainz Am Rhein, 55131, Germany
Hidaka-shi, 350-1298, Japan
Hirakata-shi, 573-1191, Japan
Kitaadachi-gun, 362-0806, Japan
Kurume-shi, 830-0011, Japan
Ogaki-shi, 503-8502, Japan
Suita-shi, 565-0871, Japan
Sunto-gun, 411-8777, Japan
Toyoake-shi, 470-1192, Japan
Hwasun-gun, 58128, South Korea
Surrey, SM2 5PT, United Kingdom